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S U M M A R Y
Background: Hospital-associated pneumonia (HAP) remains an important cause of morbidity and
mortality despite advances in antimicrobial therapy. Many aspects of the treatment of HAP caused by
multi-resistant Gram-positive microorganisms have been extensively studied, but controversial issues
remain.
Controversial issues: The aim of this GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) working group
– a panel of multidisciplinary experts – was to define recommendations for some controversial issues
using an evidence-based and analytical approach. The controversial issues were: (1) Is combination
antibiotic therapy or monotherapy more effective in the treatment of HAP? (2) What role do
pharmacokinetic/pharmacodynamic antibiotic features have as a guide in the selection of treatment for
HAP? (3) Is a de-escalation approach for the management of HAP effective? An analysis of the studies
published up until April 2009 is presented and discussed in detail.
Methods: A systematic literature search using PubMed, MEDLINE, and EMBASE databases and the
Cochrane Library was performed. A matrix was created to extract evidence from original studies using
the CONSORT method to evaluate randomized clinical trials and the Newcastle–Ottawa Quality
Assessment Scale for case–control studies, longitudinal cohorts, and retrospective studies. The GRADE
method for grading quality of evidence was applied.
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Hospital-associated pneumonia (HAP) is the second most
common nosocomial infection (after urinary tract infection) and
the most common nosocomial infection acquired in the intensive
care unit (ICU).1–3 HAP associated with mechanical ventilation –
ventilator-associated pneumonia (VAP) – has an estimated
incidence of 8–28%.4 VAP is associated with an excess of ICU stay,
increased costs,5,6 and attributable mortality.6,7
The etiologic diagnosis of VAP is notoriously difficult, and the
results of culture and sensitivity testing are almost alwaysses. Published by Elsevier Ltd. All rights reserved.
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administration of an empirical therapy is considered essential,
because inappropriate antimicrobial treatment is an important
independent determinant of mortality in patients with VAP,
regardless of the introduction of active agents after culture results
become available.8–11 The same results are obtained for Staphylo-
coccus aureus respiratory12 and bloodstream infections.13
Based on these observations, the initial therapy should be
started immediately after diagnostic specimens are obtained, even
though the optimal antimicrobial agents remain unclear, because
the microbial and resistance patterns of each local setting are
different. Therefore it is evident that recommendations for the
initial empiric antimicrobial treatmentmust be flexible enough for
modification according to local peculiarities, and also based on the
timing of the episode (early or late VAP), the severity of illness, and
previous antibiotic exposure.14
If treatment of early VAP (usually due to organisms commonly
seen in community-acquired pneumonia, such as Haemophilus
influenzae, Streptococcus pneumoniae, and methicillin-susceptible
Staphylococcus aureus (MSSA)) is relatively easy, late VAP or VAP in
a patient previously exposed to antibiotics represents a serious
problem, because pneumonia is more likely to be caused by multi-
resistant organisms such as Pseudomonas aeruginosa, Acinetobacter
spp, and methicillin-resistant S. aureus (MRSA).15,16
2. Objective
The aim of this work was to define recommendations for some
controversial issues on the management of nosocomial pneumo-
nia, using an evidence-based approach.
3. Methods
3.1. Controversial issues
The overall approach to the therapy of HAP is quite complex,
and several areas of debate remain. The Italian Study Group on
Serious Infections, GISIG, is an Italian nationwide group composed
of approximately 50 Italian experts on infectious diseases in the
hospital setting and it was committed to study the HAP
controversial issues below.
3.2. Combination versus monotherapy
To maximize the probability of adequate antibiotic coverage,
combination therapywith two ormore broad-spectrumantibiotics
is frequently advocated.14–17 In fact, treatment with multiple
antibiotics theoretically increases the likelihood of therapeutic
success through an extended spectrum of activity,18 antimicrobial
synergy, especially in the treatment of P. aeruginosa,19 and a
decreased potential for promoting resistant microorganisms.20 On
the other hand, combination therapy generally increases the cost
and is associated with greater toxicity and the risk of drug–drug
interactions; furthermore, there is a risk of the emergence ofmulti-
resistant organisms and superinfections.15,16,21
3.3. The role of pharmacokinetic (PK) and pharmacodynamic (PD)
antibiotic features as a guide to treatment selection in HAP
To achieve adequate therapy, it is necessary not only to use the
correct antibiotic (or antibiotics), but also the optimal dose and the
correct route of administration (oral, by aerosol, intravenous,
intermittently or continuously administered) to ensure that the
antibiotic(s) penetrate(s) the site of infection. When PK/PD
parameters have been applied to in vitro and animal models,
antibiotics have shown a good relationship between concentrationand response, when response is quantified as the rate of bacterial
eradication.22–24 Furthermore, most studies correlating PK/PD
measures and responses in humans have been conducted to
analyze community-acquired pneumonia25–27 and the common
opinion is that the PK/PD properties of specific antibiotics should
be considered in selecting an adequate regimen. However, the
relevance of these findings to outcomes in the therapy of HAP
remains to be defined.
3.4. De-escalation therapy
The criteria for the choice of an initial empiric antimicrobial
treatment giving an adequate coverage for the predicted micro-
organisms will lead to many patients receiving an initial broad-
spectrum therapy, because the risk factors for multidrug-resistant
(MDR) pathogens are common. This can potentially lead to
antibiotic overuse (i.e., starting antimicrobials for non-infectious
diseases or using unnecessary broad-spectrum treatments).
Among the proposed strategies to reconcile the need for an
appropriate initial empiric coverage with the need to avoid the
risks of misuse of broad-spectrum antibiotics, the so-called de-
escalation strategies have been the most valued.28,29 These
strategies have in common that, once the results of respiratory
tract (and blood culture) examinations become available, the
initial broad-spectrum empiric therapy must be focused or
narrowed (de-escalated) on the basis of the identification of
specific pathogens and their antimicrobial in vitro susceptibility.
This ‘de-escalation’ approach is supported by many authors, but
criteria for its application and the real impact on clinical outcomes
deserve further consideration.30
3.5. Literature search and study selection
3.5.1. Question 1: combination versus monotherapy
The study selection was arranged in two phases. The first phase
aimed to collect all recent reviews and guidelines based on
systematic revisions and the second phase intended to select
recent randomized controlled trials (RCTs) not included in
previous systematic revisions.
For the first step we searched PubMed (up to April 2009) and
citations of the included reviews with the terms: ((‘pneumonia’
AND ‘cross infection’) OR ‘ventilator associated pneumonia’ OR
‘nosocomial pneumonia’) AND ‘guidelines’ . We included studies
using these limits: published in the last 10 years, in humans, meta-
analysis, practice guideline, review, government publication,
guideline, English, French, Italian, Spanish. The same terms were
used for a further search in Medline, EMBASE, and the Cochrane
Library.
The second phase of the research was performed using PubMed
(up to April 2009) and citations of included trials with the terms:
((‘pneumonia’ AND ‘cross infection’) OR ‘ventilator associated
pneumonia’ OR ‘nosocomial pneumonia’) AND ‘anti bacterial
agents’ AND ‘randomized controlled trial’ . We included studies
using these limits: published in the last 2 years, in humans, clinical
trial, randomized controlled trial, clinical trial phase III, clinical
trial phase IV, comparative study, English, French, Italian, Spanish.
The same termswere used for a further search inMedline, EMBASE,
and the Cochrane Library.
In this double-step selection we detected a total of 201 studies
(167 from the first and 34 from the second search). We included all
studies fulfilling the following PICOD criteria:
 P Hospital-acquired pneumonia, including ventilator-associated
pneumonia
 I Combination antibiotic therapy
 C Antibiotic monotherapy
[(Figure_1)TD$FIG]
Figure 1. Flow-chart of studies included in the final analysis.
F. Franzetti et al. / International Journal of Infectious Diseases 14S4 (2010) S55–S65 S57 O Clinical and/or microbiological response, mortality, super-
infections and adverse events
 D Randomized controlled trials
In recent years, the question about the superiority of antibiotic
combination therapy compared with monotherapy has been the
subject of several reviews, and many scientific societies have tried
to deal with this difficult subject. For our review of the literature
we initially screened 201 meta-analyses, practice guidelines,
reviews, government publications, and guidelines.
After the exclusion of all the reviews or guidelines that had not
indicated the methodology criteria for the analysis of the literature
or that hadnot dealtwith the query ‘combination ormonotherapy?’,
only four national guidelines14,31–33 and one systematic review of
goodquality remained.34Outof the twoavailableRCTs,35,36 onlyone
was considered of high quality and was included (Figure 1).36
3.5.2. Question 2: the role of pharmacokinetic and pharmacodynamic
antibiotic features as a guide to treatment selection in HAP
We searched PubMed, Medline, EMBASE, and the Cochrane
Library (up to April 2009) and citations of included studieswith the
terms: ((‘pneumonia’ AND ‘cross infection’) OR ‘ventilator associ-
ated pneumonia’ OR ‘nosocomial pneumonia’) AND ‘Gram-positive
bacteria’ AND ‘anti bacterial agents’ AND (‘pharmacokinetics’ OR
‘pharmacodynamics’). We included studies in English, French,
Italian, and Spanish regardless of date of publication. In this search
we detected a total of 251 studies.We included all studies fulfilling
the following PICOD criteria:
 PHospital-acquired pneumonia due to Gram-positive pathogens,
including VAP and health care-associated pneumonia (HCAP)
 I Higher PK/PD values
 C Lower PK/PD values
 O Clinical and/ormicrobiological response, mortality, emergence
of antibiotic resistance
 D Comparative study in humans
After screening of the 251 articles, we excluded 244
studies because they were not comparative studies (reviews,
guidelines, expert opinions, consensus conferences, case series orcase reports), the experimental design excluded human popula-
tions (in vitro or animal models, mathematical models), the
population showed no infectious pathology (human volunteers,
chronic obstructive pulmonary disease (COPD), cystic fibrosis, etc.)
or infectious diseases other than pneumonia (otitis, endocarditis,
bacteremia, etc.), HAP was due to Gram-negative organisms or
fungi only, or there was an absence of any correlation to clinical or
microbiological outcome. Finally, observational studies that did
not provide sufficient data to calculate an odds ratio for clinical
outcome were not considered (Figure 1).
3.5.3. Question 3: de-escalation therapy
We searched PubMed, Medline, EMBASE, and the Cochrane
Library (up to April 2009) and citations of included studieswith the
terms: ((‘pneumonia’ AND ‘cross infection’) OR ‘ventilator associ-
ated pneumonia’ OR ‘nosocomial pneumonia’) AND ‘anti bacterial
agents’ AND (‘de-escalation’ OR ‘discontinuation’ OR ‘treatment
guideline’ OR ‘antibiotic guideline’). We included studies in
English, French, Italian, and Spanish, regardless of date of
publication. In this search we detected a total of 159 studies.
We included all studies fulfilling the following PICOD criteria:
 P HAP due to Gram-positive pathogens, including VAP and HCAP
 I A de-escalation strategy
 C Standard of care
 O Clinical and/ormicrobiological response, mortality, emergence
of antibiotic resistance, hospital or ICU length of stay, costs
 D RCT or other comparative study in humans
We screened 159 studies for inclusion in this review. The
principal reasons for exclusion of the study from the analysis were:
because they did not adequately compare de-escalation with a
different strategy, did not use clinical outcomemeasures, included
only patientswith Gram-negative infections, or analyzed primarily
the role of empiric therapy guided by colonization data obtained
from endotracheal aspirates. Also studies disguised as reviews
(guidelines, expert opinions and consensus conferences) were
excluded.
A total of 10 papers concerning a de-escalation strategy were
considered. However, the final analysis does not include four
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F. Franzetti et al. / International Journal of Infectious Diseases 14S4 (2010) S55–S65S58observational studies that retrospectively compared patients on
de-escalating antibiotic treatment versus patients not de-escalat-
ing.37–40 In spite of their potential interest, the retrospective nature
of these investigations introduced a high risk of bias, because of the
decision not to de-escalate antibiotics. Therefore, the final analysis
was performed on six trials (Figure 1).
3.6. Classification and evaluation of the selected evidence
Statement documents (guidelines and/or consensus statement)
and review documents (systematic review of the literature and
meta-analyses) were chosen on the basis of the presence of a
methods section with inclusion criteria, methodology used to
identify the studies, and quality evaluation of the included studies.
A matrix was made to extract evidence from each original study
using the CONSORT method for RCTs and the Newcastle–Ottawa
Quality Assessment Scale for case-control studies, longitudinal
cohorts, and retrospective studies with comparative evaluations. To
assign the strength level for each recommendation, a methodology
adapted fromtheGRADEWorkingGroupwasused.Thedetailsof the
applied methodology are published in this supplement.41
4. Results
4.1. Question 1: combination versus monotherapy
The guidelines elaborated by the American Thoracic Society
(ATS) and Infectious Diseases Society of America (IDSA) in 200514
analyzed data froma few trials.42,43 The conclusionwas that no data
have documented the superiority of antibiotic combination therapy
compared with monotherapy, except to enhance the likelihood of
initially appropriate empiric therapy. The former approach should
be used if patients are likely to be infected with MDR pathogens.
In the guidelines from Brazil and Argentina,31 on the basis of an
analysis of a few studies,44–46 the authors are convinced that
monotherapy in the treatment of HAP without MDR strains
reduces costs and unnecessary exposure to antibiotics .
The more recent guidelines of the British Society for Antimi-
crobial Chemotherapy (BSAC)32 revised the results of 16 RCTs
enrolling patients with HAP (but not exclusively) and comparing
patients receivingmonotherapywith combination therapywith an
aminoglycoside.42,43,45,47–58
From the above studies, there is no evidence that clinical or
bacteriological response rates can be improved with combination
therapy.
Finally, the VAP Guidelines Committee and the Critical Care
Trials Group from Canada33 extrapolated data from five level 2
trials,35,47–49,59 concluding that there is no advantage to antibiotic
combination therapy, because these trials did not demonstrate any
differences in mortality or clinical response rates. In addition, the
benefit of a reduction in antibiotic use and costs favors
monotherapy. However, these authors argued that knowledge of
the nature and susceptibility of the environmental pathogens
remains the cornerstone to correctly prescribe antibiotic therapy.
All guidelines agree, however, that in settings with a high
probability of MDR organisms, combination therapy is recom-
mended even if there is no clear evidence from the studies, which
suffer from lack of power and low numbers of infections caused by
MDR bacteria.
A complete evaluation of this topic is included in the systematic
review of Aarts et al. on the management of HAP.34 On the basis of
stringent criteria, the authors selected 11 trials comparing mono-
therapy with combination therapy,42,43,45,47–50,59–63 including a
totalof1805patients (85.1%ventilated).Monotherapyconsistedof a
carbapenem (n = 5), ceftazidime (n = 3), cefepime, ciprofloxacin, or
moxalactam (n = 1). Combination therapy consisted of ciprofloxacin
F. Franzetti et al. / International Journal of Infectious Diseases 14S4 (2010) S55–S65 S59combined with meropenem (n = 1), cefepime combined with
levofloxacin or amikacin (n = 1), or an aminoglycoside combined
with ceftazidime (n = 5) or other anti-pseudomonal b-lactams
(n = 4). There was no mortality difference (in the eight studies
evaluating this outcome) for patients receiving monotherapy in
comparison to combination therapy (relative risk (RR) 0.94, 0.76–
1.16). Similarly there was no significant difference in treatment
failure (RR 0.88, 0.72–1.07), rates of superinfection (RR 0.77, 0.48–
1.22), or serious adverse events (RR 0.84, 0.48–1.49). The only
evidence of superior efficacy comparing specific antibiotic regimens
was seen in six trials pooled in three comparisons showing
meropenem to be superior to a combination of ceftazidime and
anaminoglycoside in termsof clinical response (RR0.70, 0.53–0.93).
Aarts and colleagues34 concluded that there was no evidence
that combination therapy is superior to monotherapy in reducing
rates of treatment failure, superinfection, or adverse events.
Meropenem was associated with a decreased treatment failure
rate when compared with ceftazidime and aminoglycoside
combination therapy, but without differences in mortality.
However, the authors specified that thepercentage of episodes of
VAP caused by MDR or difficult-to-treat organisms was low in the
trials they reviewed, and that the initial selection of antimicrobial(s)
must be guided by consideration of local microbial ecology.
After the meta-analysis of Aarts,34 only one RCT on this topic
deserving consideration has been published. In the USA and
Canada, Heyland et al. performed a multicenter study comparing a
strategy of combination therapy (meropenem plus ciprofloxacin)
with a strategy of monotherapy (meropenem) for the treatment of
suspected late-onset VAP.35 Patients colonized or infected with P.
aeruginosa or MRSA were not included in the 740 mechanically
ventilated patients studied. Consequently, the overall prevalence
of P. aeruginosa, MRSA, and other MDR organisms was negligible
(MRSA 1.6% and MDR Gram-negative organisms 7.6%).
The relative risk of 28-day mortality in the combination group
vs. monotherapy group was 1.05 (0.78–1.42, p = 0.74) after
stratification for APACHE II score and diagnostic technique.
Duration of ICU and hospital stay, clinical and microbiological
response, emergence of antibiotic-resistant bacteria, isolation of
Clostridium difficile in stool, and fungal colonization were also
similar in the two groups.
The authors stated that monotherapy is associated with similar
outcomes compared with combination therapy, but limited their
conclusion to patients with suspected late VAP at low risk for
difficult-to-treat Gram-negative bacteria or MRSA.
4.2. Question 2: the role of pharmacokinetic and pharmacodynamic
antibiotic features as a guide to treatment selection in HAP
We identified seven studies for analytical evaluation (Tables
1 and 2). The characteristics of these studies were quite differentTable 2
Question 2: results of the studies
Study n PK/PD parameter Cli
Moise, 200067 70 AUIC 0.0
Wysocki, 200169 119b Trough, AUC <0
Moise-Broder, 200468 90 AUIC 0.0
Drusano, 200466 47 AUIC NS
Hidayat, 200670 95 Trough NS
Jeffres, 200664 102 Trough, AUC NS
Jeffres, 200765 94 Trough NE
PK/PD, pharmacokinetic/pharmacodynamic; AUIC, area under the curve on minimal in
pneumonia; LRTI, lower respiratory tract infection; MRS, methicillin-resistant staphyloc
evaluated; NS, not significant.
a High correlation with microbiological success but no p-value calculated.
bIncluding Staphylococcus spp, not only S. aureus.
cp-value not significant in multivariate analysis.and only three out of the seven studies included HAP only.
Two of these three involved the same group and included only
HCAP caused by MRSA.64,65 In the third one, including non-
severe HAP, S. aureus accounted for more than one third of the
episodes.66
Jeffres et al., in a single-center observational cohort study,
used targeted trough concentrations of 15–20 mg/l to retro-
spectively evaluate 102 patients with health care-associated
MRSA pneumonia.64 The study failed to demonstrate any
relationship between vancomycin PK indices and mortality.
The multivariate analysis identified vasopressor administration
and COPDs as the only independent determinants of hospital
mortality, even because the trough levels and area under the
curve (AUC) were very similar in survivors and non-survivors
(Table 2).
In a second study, Jeffres et al. included 94 patients with HCAP
in order to evaluate the relationship between aggressive
vancomycin dosing and nephrotoxicity.65 Patients who devel-
oped nephrotoxicity weremore likely to have higher steady-state
mean trough serum vancomycin concentrations (20.8 mg/l vs.
14.3 mg/l, p < 0.001). Longer duration (14 days) of vancomycin
therapy (45.0% vs. 20.4%, p = 0.011) was also correlated with
nephrotoxicity.
Drusano et al. retrospectively examined 47 patients with non-
severe HAP who were treated with levofloxacin, demonstrating
that a total drug AUC24/minimum inhibitory concentration (MIC)
value 87 was correlated with the eradication of Gram-negative
bacilli (p < 0.011).6 However, logistic regression analysis of clinical
outcomes revealed no link between AUC24/MIC ratio and this
parameter. In this study, a second antibiotic was added for patients
with MRSA or P. aeruginosa infection (vancomycin for MRSA and
ceftazidime or piperacillin/tazobactam for P. aeruginosa). However,
the ‘other active drugs’ covariate was not significant in univariate
analysis.
The other four studies did not completely meet the inclusion
criteria of the research, but furnish useful supplementary
information. In particular, two studies by the same group
retrospectively analyzed episodes of S. aureus lower respiratory
tract infection (LRTI) (with variable rates of MRSA, from 30% to
50%), not exclusively of nosocomial origin67,68 and two studies
analyzed a population of methicillin-resistant staphylococcal
infections, not exclusively affecting the respiratory tract.69,70
Moise et al. studied a group of 70 patients (53 clinically
evaluable and 62 microbiologically evaluable) with LRTIs caused
by S. aureus using the AUC24/MIC of vancomycin to predict clinical
and microbiological outcomes.67 The AUC24/MIC of clinical non-
responders was 380.5  218.2 mg/l (median 306 mg/l) vs.
628.3  368.1 mg/l (median 491 mg/l) for patients with successful
clinical outcomes (p = 0.001). Moreover, microbiological success
was reached in 91% of patients with AUC24/MIC >866, whereasnical response Microbiological response Nephrotoxicity
01 Yesa NE
.05c NE NE
04 0.04 NE
<0.001c NE
NA 0.01
NE NE
NE 0.01
hibitory concentration ratio; ID, immunodepression; HCAP, health care-associated
occi; MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable; NE, not
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F. Franzetti et al. / International Journal of Infectious Diseases 14S4 (2010) S55–S65S60patients with AUC24/MIC <866 had only a 39% success rate (no
statistical analysis is presented). Authors concluded that AUC24/MIC
predicts clinical and microbiological outcomes of vancomycin
therapy in patients with S. aureus LRTI. However, a multivariate
analysis of other risk factors potentially correlated to the outcomes
was not available.
In another study, the same group aimed to determine whether
the time that vancomycin serum concentrations exceed the MIC
(%time > MIC) is as good a determinant of response as its AUC24/
MIC value and to examine the time to bacterial eradication for
vancomycin in relation to achieved AUC24/MIC values.
68 The
stepwise logistic regression identified five statistically significant
factors associated with improved clinical outcome, among them
AUC24/MIC >350 (OR 7.19, p = 0.004) was the more important.
Moreover, the time to bacterial eradication was significantly lower
in patientswith an AUC24/MIC > 400 (median 10 days vs. an excess
of 30 days, p = 0.04). Finally, all the patients in the study (both
successes and failures) had %time > MIC = 100%, establishing that
this target is not predictive of outcome. The authors concluded that
the AUC24/MIC ratio predicts time-related clinical and bacterio-
logical outcomes for patients with LRTI caused by MRSA and
appears to be the major pharmacodynamic index correlating with
infection response.
In a multicenter, prospective, randomized study, Wysocki
et al. evaluated 119 patients with severe hospital-acquired
staphylococcal infections (pneumonia, 45%), of which 80% were
methicillin-resistant.69 The aim of the study was to determine
which modality of vancomycin infusion is more efficient, safer,
easier to adjust, and more cost-effective. Two schemes were
compared: intermittent vancomycin infusion (IVI) and continu-
ous vancomycin infusion (CVI). Trough concentrations and AUC24
were higher for patients who failed in comparison with those
with treatment success (p < 0.05 in univariate analysis). How-
ever, a multivariate analysis found that only the severity of the
underlying disease at admission (p < 0.05) and the day-10 serum
creatinine concentrations (p < 0.02) were associated with
treatment failure. Reduced costs (calculated for 10 days and
defined as the cost of vancomycin infused plus the cost of
monitoring vancomycin concentrations in serum) were obtained
with CVI. The conclusion of the investigators was that no
difference in patient outcome was observed between those
receiving intermittent and those receiving continuous infusion of
vancomycin.
Hidayat et al. investigated 95 elderly patients with health
care-associated infections due to MRSA.70 Most isolates came
from the respiratory tract (52%), and co-infection with P.
aeruginosa and/or Enterobacteriaceae was present in 28% of
patients with pneumonia. Vancomycin MIC values of 1.5 or 2 mg/
l were found in 54% of the patients. The authors evaluated the
efficacy and risk of nephrotoxicity after the use of high-dose
vancomycin intended to achieve unbound trough serum vanco-
mycin concentrations of at least four times the MIC. Patients
infected with MIC >1 mg/l strains had a poorer response (62% vs.
85%) and a significantly higher infection-related mortality (24%
vs. 10%), despite achieving target trough serum vancomycin
concentrations of 15–20 mg/l. In a multivariate analysis, the MIC
of the infected strains and APACHE II score (p = 0.03 and 0.009,
respectively) were independent predictors of poor treatment
response when controlled for target trough attainment. Con-
comitant nephrotoxic agents (p < 0.001), high vancomycin
trough level (p = 0.03), and duration of vancomycin therapy
(p = 0.004) significantly predicted nephrotoxicity. By controlling
for other factors (including vancomycin trough levels and
duration of therapy) in a multivariate analysis, concomitant
nephrotoxic agents remained the most significant predictor of
nephrotoxicity (p = 0.003).
Table 4
Question 3: results of the studies
Study n Mortality Appropriate
antibiotic
Duration of
antibiotic
LOS
hospital
LOS ICU Clinical
response
Colonization Induction of
resistance
Super
infection
Cost
Prospective randomized controlled trials comparing protocols of early discontinuation vs. common practice
Singh, 200071 81 NS NE 0.0001 NE 0.04 NS NE 0.017 0.0001 0.003
Micek, 200473 290 NS NE 0.001a NS NS NE NE NE NS NE
Before and after studies comparing guidelines-oriented de-escalation strategy vs. common practice
Ibrahim, 200174 102 NS <0.001 <0.001 NS NS NE NSb NE 0.03 NE
Soo Hoo, 200575 117 0.03c <0.01 NE NS NS NE NS NS NE NE
Dellit, 200876 819 NS 0.001d 0.001e NE NE NE NE NE NE NE
Lancaster, 200877 100 NS 0.005f 0.001 NS NS NE NE NE NE NE
LOS, length of stay; ICU, intensive care unit; NE, not evaluated; NS, not significant.
a Statistical significance was <0.001 in the subgroup of Gram-positive pneumonia.
b Only colonization by vancomycin-resistant enterococci was considered.
c Mortality at 30 days was not significant.
d Initial empiric antibiotic therapy was not significant, but definitive antibiotic treatment was significant.
e Statistical significance was 0.009 in the methicillin-susceptible Staphylococcus aureus subgroup and 0.042 in methicillin-resistant Staphylococcus aureus subgroup.
f Different analyses to evaluate appropriateness.
F. Franzetti et al. / International Journal of Infectious Diseases 14S4 (2010) S55–S65 S614.3. Question 3: de-escalation therapy
Afirst attempt to evaluate a strategy of de-escalation in patients
with VAP was proposed by Singh et al.,71 and adopted an approach
using the first five variables of the clinical pulmonary infection
score (CPIS)72 – temperature, blood leukocyte count, tracheal
secretions, oxygenation, and character of pulmonary infiltrate – as
criteria to identify patients for whom a shorter course of antibiotic
therapywould suffice. In their RCT, these investigatorswere able to
demonstrate that pneumonia can be reasonably excluded and
empirical antibiotic therapy stoppedwhen the CPIS falls below 6 at
baseline and again at 3 days. Notwithstanding the limited number
of patients included in the study (n = 81), overall, a substantial
reduction in antibiotic use (p = 0.0001) and costs (p = 0.003), and in
length of stay (p = 0.0001) was observed. Moreover, antimicrobial
resistance, or superinfections, or both, developed in 15% of the
patients in the discontinuation group versus 35% of the patients in
the standard therapy group (p = 0.017).
More recently, Micek et al. evaluated an easy antibiotic
discontinuation policy for VAP based on the presence of one of the
following conditions: (1) non-infectious etiology for the infiltrates;
and (2) signs and symptoms suggesting active infection resolution.73
The antibiotic treatment at baselinewas a combinationof linezolid or
vancomycin plus cefepime plus ciprofloxacin or gentamicin. The
authors also decided to include patients without isolation of
pathogenic microorganisms in their respiratory cultures, and
considered them adequately treated (20% and 25% in the discontinu-
ationandconventionalgroups, respectively). Thedataanalysis for the
290 patients completing this RCT demonstrated a shorter duration of
antibiotic treatment in the discontinuation group (p = 0.001).
Moreover, the occurrence of a secondary episode of VAP and hospital
and ICU length of stay were no different between the two groups.
These strategies of early discontinuation are similar to the
concept of de-escalation, but are based on an early re-discussion of
the diagnosis (yes/no) of pneumonia rather than on the pathogen
and its susceptibility pattern.
The validity of a multi-step protocol of de-escalation has been
verified in the prototype study of Ibrahim et al.,74 which confirmed
the three ‘before and after’ investigations performed in recent
years by Soo Hoo et al., Dellit et al., and Lancaster et al.75–77 The
model guide for the de-escalation of antibiotics did not signifi-
cantly diverge from the ATS guidelines in all the studies, which
differed principally in the patient inclusion criteria (see Table 3)
and in the criteria for dealing with patients without a bacterial
isolation. All the studies evaluated mortality and appropriateness
of antibiotic treatment, but in the definition of this latter item all
the studies considered only the activity in vitro against the
identified bacterial species associated with HAP.As summarized in Tables 3 and 4, all these publications have
demonstrated the positive impact of institution-specific guidelines
for themanagement of HAP patients with different characteristics:
HCAP,76 severe HAP,75 and VAP.74,77 The benefits include
improvements in the appropriateness of empirical therapy,74,75,77
reduction in duration of antibiotics,74,76,77 development of
secondary episodes of VAP by MDR bacteria, colonization by
vancomycin-resistant enterococci (VRE),74 and mortality at 14
days.75 In none of the studies was protocol-guided de-escalation
inferior in whatever parameter in comparison with the clinical
judgment of the physician as observed in the ‘before period’. All
these investigations are inevitably affected by the limits of this
type of study: although the authors tend to demonstrate the
comparability of the two periods under examination, multiple
factors influencing outcomes are varied and determine the results
of the studies. Notably, in the protocols of three out of the four
studies, a time limit of 7–8 days for the duration of the antibiotic
treatment was included, after which the therapy had to be
interrupted (except for patients with Gram-negative pathogens,
such as P. aeruginosa and Acinetobacter baumannii, in which case a
longer duration of 15 days was recommended).74,76,77
5. From the evidence to the recommendations
5.1. Question 1: combination versus monotherapy
5.1.1. Discussion
The analysis of several RCTs comparing monotherapy with
combination treatment in the antibiotic treatment of HAP, does not
substantiate any advantage for combination therapy34 (GRADE
score 1). There are several limitations in these trials. They were
often performed in heterogeneous populations and this may have
diluted the impact of particular antibiotic regimens in patients
with a specific diagnosis of VAP. They were generally small,
without the power to detect differences in outcomes between the
treatment groups. They did not evaluate the timing of administra-
tion, which could be a factor more important than the type of
antibiotic(s) administered. However, the major limitation is the
very low percentage of episodes of VAP caused by MDR bacteria.
Therefore, the proposal of an antibiotic monotherapy has to be
reserved for settings in which MRSA or other difficult-to-treat
pathogens are not frequently found.
Meropenem was associated with a decreased treatment failure
rate when compared with ceftazidime and aminoglycoside
(tobramycin or amikacin) combination therapy43,47 (GRADE score
2 for both). This effect, however, did not translate into a difference
in mortality. On the other hand, double b-lactam or b-lactam–
fluoroquinolone combinations have not been studied adequately.
Recommendations
F. Franzetti et al. / International Journal of Infectious Diseases 14S4 (2010) S55–S65S62Because of their design, the data available from pertinent RCTs
do not allow any conclusions to be drawn on the potential
advantages of also prescribing a drug that is active againstMRSA or
otherMDRGram-positive agents in the initial empiric treatment of
VAP, which is a frequent practice where MRSA is endemic. In
published studies, initially untreatedMRSA often appears to be the
cause of treatment failure,78,79 but no specific trials testing initial
coverage also of MRSA against a comparator arm without this
coverage, are available. Several studies have investigated the
efficacy of linezolid, vancomycin, teicoplanin, and ceftobiprole in
the treatment of HAP80–82 (GRADE score 4, 4, 0, respectively) and
severe pneumonia83,84 (GRADE score 1 for both), but have always
compared two potentially active treatments.
Therefore, additional studies are needed to provide advice to
clinicians on the optimal agents and dosages for treating HAP in
patients with risk factors for MRSA. Up-to-date guidelines could be
used to correctly identify these patients14 (quality level 2).We encourage the use of PK/PD parameters such as AUC24/
MIC ratio, at least for critically ill patients with HAP, for the
prevention of both failure and resistance (B). Because it can be
difficult in the clinical setting to obtain multiple serum
vancomycin concentrations to determine the AUC and subse-
quently the AUC24/MIC, trough serum vancomycin concentra-
tion monitoring can be recommended whenMIC is available, in
attempting to increase trough serum vancomycin concentra-
tions to 15–20 mg/l to obtain a desirable AUC/MIC of 400 (C).
Because the target attainment of an AUC24/MIC of 400 for
vancomycin is not likely in patients with S. aureus infections
who have a MIC of >1 mg/l, treatment with alternative agents
should be considered (C).
Monitoring of trough serum vancomycin concentrations to
reduce nephrotoxicity is recommended for patients receiving
aggressive dosing (>30 mg/kg) and/or receiving concurrent
nephrotoxic drugs and/or with unstable renal function and/or
Recommendations
The initial selection of the antimicrobial regimen for HAP
must be guided by consideration of the local microbial ecology.
In populations of patients at low risk of MDR (including MRSA)
or difficult to-treat pathogens, therapy with a single antibiotic
may be adequate (A).
We advocate that in patients with HAP at risk for MRSA,
initial empiric combination therapy including linezolid or a5.2. Question 2: the role of pharmacokinetic and pharmacodynamic
antibiotic features as a guide to treatment selection in HAP
5.2.1. Discussion
The investigations described herein are often limited by a small
sample size, retrospective design, and questionable methodology.
None of the studies evaluatedmortality as an outcome and only the
study of Wysocki included an analysis of costs69 (GRADE score 4).
Based on these study results, there are no conclusive data
suggesting a strong correlation between PK (trough concentration
and AUC) and clinical outcome in HAP64,65,69,70 (GRADE score 2, 2,
4, 2, respectively).
Regarding PD parameters, the AUC24/MIC has been correlated
withmicrobiological outcomefor levofloxacin66 (GRADEscore3) and
with bothmicrobiological and clinical outcome for vancomycin.67,68
(GRADE score 1 and 4, respectively). AnAUC24/MIC ratio of350 has
been advocated as a target for the achievement of clinical efficacy
with vancomycin68 (GRADE score 4), and of 87 for levofloxacin66
(GRADE score 3). According to current understanding, AUC24/MIC is
likely the PK/PD surrogate marker that better predicts clinical
efficacy, although the main data on vancomycin were obtained in a
population with S. aureus LRTI, not exclusively nosocomial. Even
though data regarding Gram-positive infections are lacking, litera-
ture data on Gram-negative pneumonia shows favorable results in
the correlation between AUC24/MIC and clinical as well as
microbiological outcome85 (GRADE score 1) and in the adjustments
of dosing based on PK/PD parameters86 (GRADE score 1).
The studies analyzing the relationship between vancomycin
levels and nephrotoxicity in patientswithMRSA infections showed
that higher trough serum vancomycin levels may increase the
potential for toxicity65,70 (GRADE score 2 for both). However, these
limited data are characterized by the presence of confounding
nephrotoxic agents70 (GRADE score 2) and by the difficulties in
examining the timing of the relationship between high vancomy-
cin levels and nephrotoxicity (i.e., which one precedes the other).
glycopeptide should be prescribed and rationalized based on
culture results (see also de-escalation strategy) (D).However, Darko et al., investigating patients with different
infections, found therapeutic drug monitoring to be cost-effective
among ICU patients and those receiving other nephrotoxic
drugs87(GRADE score 1). Therefore, additional clinical experience
is required to determine the extent of this potential in the
management of patients with HAP.
Concentrations in epithelial lining fluid (ELF) greater than or
equal to those in the serum achieved by some antibiotics
(fluoroquinolones, macrolides, and linezolid) may contribute to
enhanced efficacy88–91(GRADE score 1 for each). However,
vancomycin has been shown to have lower penetration into the
ELF and respiratory secretions92,93 (GRADE score 1 for both). It is
not clear whether these differences relate to clinical outcomes in
patients with HAP, because studies analyzing ELF levels of
antibiotics and clinical outcomes in HAP are not available.5.3. Question 3: de-escalation therapy
5.3.1. Discussion
The use of protocols for the de-escalation of antibiotics in the
management of HAP based on international guidelines and local
microbiological data have demonstrated positive results. The major
impact identified in the ‘beforeandafter’ investigationswas in terms
of appropriateness of empirical therapy74–77 (GRADE score 3, 3, 2, 4,
respectively) and reduction in duration of antibiotics74,76,77 (GRADE
score 3, 2, 4, respectively). Furthermore, retrospective observational
studies also suggest that de-escalation therapymay be safe, because
under no circumstances was prolonged broad-spectrum empirical
antibiotic therapy superior to de-escalation regimens37–40,94
(GRADE score 1 for each). However, the comparisons remain
doubtful in that one well-standardized strategy (de-escalation
protocol) is tested against a clinical strategy that could reflect an
incorrect clinical practice. Therefore the true use of targeted therapy
in all patients with VAP should be confirmed through the conduct of
RCTs comparing early empiric therapy to a strategy of delayed
therapy based on culture results.
There are limited data concerning the optimal duration of
therapy for patients with HAP. A recent RCT showed no statistically
significant differences in mortality and recurrences of pneumonia,
comparing 8 versus 15 days of antibiotic treatment95 (GRADE score
3). The only exception was the higher rates of recurrence among
patients infected with non-lactose-fermenting bacteria (P. aerugi-
nosa and Acinetobacter). Consequently, most of the de-escalation
protocols recommend a 7- or 8-day course of adequate antibiotic
receiving prolonged courses of therapy (over 5 days) (B).
F. Franzetti et al. / International Journal of Infectious Diseases 14S4 (2010) S55–S65 S63therapy. A duration of 15 days has been suggested for patients
infected with P. aeruginosa or A. baumannii or if there is a lack of
clinical improvement, based on a CPIS score >6 on day 876 (GRADE
score 2).
The rates of de-escalation vary among studies and adherence
to guidelines for VAP is also highly variable96,97 and obviously
dependent on a high-quality microbiological diagnosis. Several
studies have shown that once broad-spectrum empiric anti-
biotics are initiated they are rarely discontinued, even when
culture results are negative98,99 (GRADE score 1 for both).
Frequently, the high proportion of patients with negative
cultures who were not de-escalated appears to be influenced
by the lack of specific recommendations for discontinuation of
therapy. On the other hand, the adoption of precise criteria to
stop therapy in culture-negative episodes of suspected VAP has
shown good results73 (GRADE score >4). In particular, antibiotic
interruption should be considered if the CPIS score remains
below 6 on the third day of therapy71 (GRADE score >4). This
strategy could also have an impact on the long-term develop-
ment of resistance.Recommendations
The use of a de-escalation strategy in the antimicrobial
treatment of HAP based on an institutional protocol that
incorporates local resistance patterns, is recommended. This
strategy requires that following the initiation of an empirical
broad-spectrum antibiotic therapy (based on patient risk
factors and clinical presentation), the therapy be tailored to
the specific pathogen(s) identified in microbiological cultures,
by changing to a narrower spectrum treatment or to stop
antibiotics if the diagnosis of HAP is not confirmed. There
should be periodic revision and control of the strict application
of the protocol (B).
Protocols for VAP management should provide recommen-
dations for empirical therapy as well as for de-escalation and
duration of therapy, which should not continue for more than 8
days in patients with a confirmedmicrobial etiology. We advise
a 15-day antibiotic treatment for pneumonia caused by P.
aeruginosa or A. baumannii or in the absence of clinical
improvement on day 8 of treatment (B). Data in the literature
are not sufficient to include MRSA in this group of microorgan-
isms requiring a more prolonged treatment (D).
Protocols should be precise with regard to the criteria for
discontinuation of antibiotic therapy if the diagnosis of
pneumonia remains uncertain or negative (for example CPIS
<6 at day-3 of therapy) (B).Acknowledgement
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